BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 24814041)

  • 1. Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?
    Chevolet I; Speeckaert R; Haspeslagh M; Neyns B; Krüse V; Schreuer M; Van Gele M; Van Geel N; Brochez L
    Br J Dermatol; 2014 Nov; 171(5):987-95. PubMed ID: 24814041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients.
    Speeckaert R; Vermaelen K; van Geel N; Autier P; Lambert J; Haspeslagh M; van Gele M; Thielemans K; Neyns B; Roche N; Verbeke N; Deron P; Speeckaert M; Brochez L
    Eur J Cancer; 2012 Sep; 48(13):2004-11. PubMed ID: 22033321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FoxP3 and indoleamine 2,3-dioxygenase immunoreactivity in sentinel nodes from melanoma patients.
    Ryan M; Crow J; Kahmke R; Fisher SR; Su Z; Lee WT
    Am J Otolaryngol; 2014; 35(6):689-94. PubMed ID: 25212103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indoleamine 2,3-Dioxygenase Expression in Primary Cutaneous Melanoma Correlates with Breslow Thickness and Is of Significant Prognostic Value for Progression-Free Survival.
    Rubel F; Kern JS; Technau-Hafsi K; Uhrich S; Thoma K; Häcker G; von Bubnoff N; Meiss F; von Bubnoff D
    J Invest Dermatol; 2018 Mar; 138(3):679-687. PubMed ID: 29054599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular analysis of melanoma-induced sentinel lymph node immune dysfunction.
    Lee JH; Chen Y; Chan JL; Qian YW; Goydos JS
    Cancer Immunol Immunother; 2011 May; 60(5):685-92. PubMed ID: 21327637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.
    Taylor RC; Patel A; Panageas KS; Busam KJ; Brady MS
    J Clin Oncol; 2007 Mar; 25(7):869-75. PubMed ID: 17327608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of FoxP3+ regulatory T cells and IDO+ immune and tumor cells in malignant melanoma - an immunohistochemical study.
    Salmi S; Lin A; Hirschovits-Gerz B; Valkonen M; Aaltonen N; Sironen R; Siiskonen H; Pasonen-Seppänen S
    BMC Cancer; 2021 May; 21(1):641. PubMed ID: 34051744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of indoleamine 2,3-dioxygenase and infiltration of FOXP3+ regulatory T cells are associated with aggressive features of papillary thyroid microcarcinoma.
    Ryu HS; Park YS; Park HJ; Chung YR; Yom CK; Ahn SH; Park YJ; Park SH; Park SY
    Thyroid; 2014 Aug; 24(8):1232-40. PubMed ID: 24742251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival.
    Ino K; Yamamoto E; Shibata K; Kajiyama H; Yoshida N; Terauchi M; Nawa A; Nagasaka T; Takikawa O; Kikkawa F
    Clin Cancer Res; 2008 Apr; 14(8):2310-7. PubMed ID: 18413819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection.
    Witkiewicz A; Williams TK; Cozzitorto J; Durkan B; Showalter SL; Yeo CJ; Brody JR
    J Am Coll Surg; 2008 May; 206(5):849-54; discussion 854-6. PubMed ID: 18471709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inter- and intrapatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment.
    Gide TN; Allanson BM; Menzies AM; Ferguson PM; Madore J; Saw RPM; Thompson JF; Long GV; Wilmott JS; Scolyer RA
    Histopathology; 2019 May; 74(6):817-828. PubMed ID: 30589949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases.
    Kakavand H; Vilain RE; Wilmott JS; Burke H; Yearley JH; Thompson JF; Hersey P; Long GV; Scolyer RA
    Mod Pathol; 2015 Dec; 28(12):1535-44. PubMed ID: 26403784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain.
    Herrera-Rios D; Mughal SS; Teuber-Hanselmann S; Pierscianek D; Sucker A; Jansen P; Schimming T; Klode J; Reifenberger J; Felsberg J; Keyvani K; Brors B; Sure U; Reifenberger G; Schadendorf D; Helfrich I
    Front Immunol; 2020; 11():120. PubMed ID: 32117271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-infiltrating lymphocytes predict cutaneous melanoma survival.
    Fortes C; Mastroeni S; Mannooranparampil TJ; Passarelli F; Zappalà A; Annessi G; Marino C; Caggiati A; Russo N; Michelozzi P
    Melanoma Res; 2015 Aug; 25(4):306-11. PubMed ID: 25933208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ki-67 expression in melanoma. A potential method of risk assessment for the patient with a positive sentinel node.
    Pearl RA; Pacifico MD; Richman PI; Stott DJ; Wilson GD; Grobbelaar AO
    J Exp Clin Cancer Res; 2007 Mar; 26(1):109-15. PubMed ID: 17550139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer.
    Yu J; Du W; Yan F; Wang Y; Li H; Cao S; Yu W; Shen C; Liu J; Ren X
    J Immunol; 2013 Apr; 190(7):3783-97. PubMed ID: 23440412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of local immunosuppression in cutaneous melanoma.
    Polak ME; Borthwick NJ; Gabriel FG; Johnson P; Higgins B; Hurren J; McCormick D; Jager MJ; Cree IA
    Br J Cancer; 2007 Jun; 96(12):1879-87. PubMed ID: 17565341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma.
    Riesenberg R; Weiler C; Spring O; Eder M; Buchner A; Popp T; Castro M; Kammerer R; Takikawa O; Hatz RA; Stief CG; Hofstetter A; Zimmermann W
    Clin Cancer Res; 2007 Dec; 13(23):6993-7002. PubMed ID: 18056175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FoxP3 and IDO in Canine Melanocytic Tumors.
    Porcellato I; Brachelente C; De Paolis L; Menchetti L; Silvestri S; Sforna M; Vichi G; Iussich S; Mechelli L
    Vet Pathol; 2019 Mar; 56(2):189-199. PubMed ID: 30381008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
    Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
    Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.